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Myc oncoproteins directly regulate transcription by
binding to target genes, yet this only explains a frac-
tion of the genes affected by Myc. mRNA turnover
is controlled via AU-binding proteins (AUBPs) that
recognize AU-rich elements (AREs) found within
many transcripts. Analyses of precancerous and
malignant Myc-expressing B cells revealed that
Myc regulates hundreds of ARE-containing (ARED)
genes and select AUBPs. Notably, Myc directly
suppresses transcription of Tristetraprolin (TTP/
ZFP36), an mRNA-destabilizing AUBP, and this
circuit is also operational during B lymphopoiesis
and IL7 signaling. Importantly, TTP suppression is
a hallmark of cancers with MYC involvement, and
restoring TTP impairs Myc-induced lymphomagene-
sis and abolishes maintenance of the malignant
state. Further, there is a selection for TTP loss in
malignancy; thus, TTP functions as a tumor sup-
pressor. Finally, Myc/TTP-directed control of select
cancer-associated ARED genes is disabled during
lymphomagenesis. Thus, Myc targets AUBPs to
regulate ARED genes that control tumorigenesis.
INTRODUCTION
Myc family oncoproteins (c-Myc, N-Myc, and L-Myc) are acti-
vated in over half of human cancers, where they regulate critical
pathways that contribute to tumorigenesis (Meyer and Penn,
2008). c-Myc (hereafter Myc) expression is activated by MYC/
Immunoglobulin (Ig) chromosomal translocations in human
Burkitt lymphoma (BL) (Dalla-Favera et al., 1982; Taub et al.,
1982). This event is sufficient to promote tumorigenesis as
Em-Myc transgenics, a mouse model of human BL where
c-Myc is under the control of the Ig Em enhancer, develop
aggressive B cell lymphoma (Adams et al., 1985). The Em-Myc
model has proven remarkably useful as a platform for discovery
of pathways activated by Myc and for defining checkpointsbypassed during tumorigenesis, for example the Arf-p53 tumor
suppressor apoptotic pathway (Eischen et al., 1999), the Myc-
to-p27Kip1 proliferative circuit (Keller et al., 2007), and the DNA
damage response (Gorrini et al., 2007).
Myc oncoproteins function as basic-helix-loop-helix leucine
zipper (bHLH-Zip) transcription factors that control the ex-
pression of a large cast (>1,600) of genes (Zeller et al., 2003) by
binding to specific E-box sequences (CAC/AGTG). Binding of
Myc to these elements requires dimerization with Max, a bHLH-
Zip family member and binding of Myc:Max complexes recruits
transcriptional coactivators to induce transcription (Dang et al.,
2006). Further, Myc:Max heterodimers repress transcription by
binding to and inhibiting the functions of the Miz-1 transcription
factor at Initiator (Inr) elements found at some transcription start
sites (Seoane et al., 2001; Staller et al., 2001). However, Myc
binding does not always connote direct regulation of a target
(Zeller et al., 2006), andMyc can indirectly affect gene expression
via its regulation of other mediators or by its effects on cell
growth, survival or transformation (Dang, 1999).
The regulation of mRNA turnover is a critical node for control-
ling gene expression, and many short-lived transcripts harbor
AU-rich elements (AREs), usually an AUUUA sequence, within
their 30 untranslated regions (30 UTRs). Indeed, using computa-
tional analysis an ARE database (ARED) has shown that at
least 11% of human genes contain AREs (Halees et al., 2008).
A set of RNA-binding proteins coined AU-binding proteins
(AUBPs) specifically bind to AREs, serving to either stabilize or
promote destruction of mRNAs (Chen and Shyu, 1995). For
example, the AUBPs HuR, HuB, HuC, HuD, Auf1, Auf2, and
Nucleolin (Ncl), typically stabilize ARE-containing mRNAs
(Brennan and Steitz, 2001; Dean et al., 2002; Sengupta et al.,
2004). In contrast, binding of others such as Tristetraprolin
(TTP/Tis11/Zfp36) and its family members Tis11b (Brf1/
Zfp36l1) and Tis11d (Brf2/Zfp36l2) mark ARE-containing mRNAs
for delivery to processing bodies (P-bodies) where transcripts
are deadenylated and degraded by mRNA decay enzymes
(Blackshear, 2002; Franks and Lykke-Andersen, 2007).
The ability of AUBPs to control gene expression through
mRNA stability has been suggested to play roles in tumorigen-
esis. For example, HuR binds to the COX-2 mRNA ARE in
colon cancer cells, increasing levels of this proinflammatoryCell 150, 563–574, August 3, 2012 ª2012 Elsevier Inc. 563
Figure 1. Myc Alters the Expression of
Hundreds of Genes Containing AREs
(A and B) Gene expression profiling of arrays
showing genes from the ARED Organism data-
base whose expression is specifically altered in
B220+ B cells from premalignant Em-Myc (n = 5)
and wild-type (n = 4) mice (A) and in Em-Myc
lymphomas (n = 13) compared to premalignant
Em-Myc B cells (B). All probe sets shown have a >
2.0-fold change and are significantly altered by
unpaired t test analysis (p < 0.05).
(C) Gene expression profiling comparing ARED
genes differentially expressed between 44 human
BL and 129 human non-BL samples from
GSE4475. All probe sets shown have >2.0-fold
change and are significantly altered by unpaired t
test analysis (p < 0.05).
See also Figure S1 and Tables S1–S3.protein (Dixon et al., 2001). Further, the NPM-ALK oncoprotein
phosphorylates AUF1, augmenting its ability to stabilize some
mRNAs (Fawal et al., 2006). In addition, b-actin promoter-driven
expression of the p37 isoform of AUF1 can trigger sarcoma
in transgenic mice (Gouble et al., 2002). Conversely, TTP levels
are reduced in aggressive prostate and breast cancer and con-
note poor outcome (Brennan et al., 2009), and inactivation of
both Tis11b and Tis11d in mouse T cells can lead to leukemia
(Hodson et al., 2010). Thus, although largely anecdotal, these
studies suggest that at least some AUBPs play roles in cancer.
Because mRNA stability is a common mechanism for con-
trolling transcript levels, we hypothesized that Myc indirectly564 Cell 150, 563–574, August 3, 2012 ª2012 Elsevier Inc.regulates ARE-containing mRNAs via the
agency of AUBPs and that this pathway
is important for tumorigenesis. Here, we
show that Myc regulates the expres-
sion of hundreds of ARED genes and
several AUBPs. In particular, Myc directly
suppresses the transcription of TTP,
which regulates the levels of cancer-
associated ARED genes, and this con-
trol is disabled during tumorigenesis.
Notably, repression of TTP is a hallmark
of malignancies with MYC involve-
ment and enforced expression of TTP
impairs lymphoma development and
abolishes maintenance of the malignant
state. Thus, TTP functions as a tumor
suppressor.
RESULTS
Myc Regulates the Expression
of ARE-Containing mRNAs
To assess effects of Myc on the expres-
sion of ARED genes (Halees et al.,
2008), we performed expression profiling
analyses of B220+ B cells from 4- to 6-
week-old wild-type versus Em-Myc litter-mates, and of lymphomas from several Em-Myc mice; 153
ARED genes, or 7.8% of ARED genes expressed, were signifi-
cantly altered in precancerous Em-Myc B cells (74 induced and
79 repressed) (Figure 1A, Table S1). Most of these were similarly
regulated in lymphomas, although the magnitude of this
response was often greater in tumors (Figure S1A). Further,
a comparison of precancerous and malignant Em-Myc B cells
showed 344 ARED genes (16.5% of ARED genes expressed)
were significantly altered by neoplastic conversion (Figure 1B,
Table S2). Collectively, the expression of nearly 20% of all
ARED genes expressed in B cells is altered during Myc-driven
lymphomagenesis.
Figure 2. Myc Alters the Expression of
AUBPs
(A, B, and E) Gene expression profiling of arrays
showing differentially expressed AUBP genes in
B220+ B cells from premalignant Em-Myc versus
wild-type littermates (A), Em-Myc lymphomas
compared to premalignant Em-Myc B cells (B) and
human BL and non-BL samples (E) fromGSE4475.
All probe sets shown have > 2.0-fold change and
are significantly altered by unpaired t test analysis
(p < 0.05).
(C and F) qRT-PCR analysis of total RNA isolated
from B220+ B cells of wild-type and premalignant
Em-Myc mice and lymphomas that arose in inde-
pendent Em-Myc transgenics (C), and of RNA of
CD19+ B cells from a healthy individual compared
to human BL samples (F). The relative expres-
sion was determined for TTP (ZFP36), TIS11B
(ZFP36L1), HUR, AUF1, AUF2, and NCL (Nucleo-
lin). Individual samples are indicated by circles
and the mean for each group is represented by
a line. Results were normalized to the expression
of Ubiquitin (Ub).
(D) Immunoblots comparing the levels of TTP,
Actin, and Tubulin in B220+ B cells of wild-type
and premalignant Em-Myc littermates.
Student’s t test (*p < 0.05, **p < 0.01, ***p < 0.001).
See also Figure S2.To assess whether MYC alters ARED gene expression in
human B lymphoma, we queried expression data sets of primary
human BL samples that bear MYC/Ig translocations versus
other human B lymphoma subtypes (non-BL) (Hummel et al.,
2006). Indeed, 366 ARED genes (15.2% of ARED genes ex-
pressed) are significantly different in human BL (Figure 1C,
Table S3). Altered ARED gene regulation is also manifest in
neuroblastoma, where analyses of expression data sets (Wang
et al., 2006) demonstrated 129 ARED genes significantly differ
in MYCN-amplified versus non-MYCN-amplified tumors (Fig-Cell 150, 563–57ure S1B). Finally, there is a significant
(24%) overlap in the expression of ARED
genes altered in BL andMYCN-amplified
neuroblastoma. Thus, Myc affects ex-
pression of a large cast of ARED genes
in different tumor types and in B cells.
The Expression of AUBPs Is Altered
During Myc-Driven
Lymphomagenesis
Given the effects of Myc on ARED genes,
expression data sets were mined to
determinewhetherMyc alters the expres-
sion of AUBPs. The expression of Ncl
and Auf2 was significantly increased in
premalignant Em-Myc versus wild-type
B220+ B cells (Figure 2A). Further, levels
of TTP, Tis11b, and Auf2 were sig-
nificantly reduced in malignant versus
precancerous Em-Myc B cells (Figure 2B).The differences in Auf2 expression are likely due to different
probe sets, one recognizing both spliced variants, whereas the
other only recognizes the shorter isoform. Quantitative real
time PCR (qRT-PCR) analyses of wild-type and premalignant
Em-Myc B cells, and of Em-Myc lymphomas, demonstrated
that TTP and Tis11b transcripts were markedly reduced in
precancerous and malignant Em-Myc B cells (Figure 2C). TTP
protein levels were also drastically reduced in premalignant
Em-Myc B cells (Figure 2D). In contrast, mRNAs encoding
HuR, Auf1, Auf2, and Ncl were elevated in precancerous and4, August 3, 2012 ª2012 Elsevier Inc. 565
malignant Em-Myc B cells (Figure 2C). Thus, the expression of
select AUBPs is altered during Myc-driven lymphomagenesis.
Suppression of TTP Family Members is a Hallmark
of Malignancies with MYC Involvement
To assess AUBP gene expression in human tumors with MYC
involvement, we determined their expression in human BL
versus non-BL lymphomas. TTP and TIS11B expression is
markedly repressed in human BL (Figures 2E and 2F). By
contrast, levels of HUR, AUF1, AUF2, and NCL mRNA were
not significantly altered. Notably, expression analyses of other
cancers and tumor subtypes established that repression of
TTP, or of its family member TIS11D, are hallmarks of Myc-
expressing malignancies. Strikingly, TTP expression was the
inverse of MYC in human tumors, where TTP levels were low in
MYC-expressing breast, colorectal, and metastatic prostate
cancer (Figures S2B–S2E). Further, TIS11D is repressed in
MYCN-amplified neuroblastoma and in colorectal cancers with
elevated MYC levels (Figures S2A and S2C).
A Myc-TTP Circuit is also Operational in B Lymphocytes
The finding that TTP levels inversely correlated with MYC in
tumors versus normal tissues suggested that Myc and TTP
expressionmight be coordinately controlled during development
and bymitogenic signaling. In progenitor B cellsMyc is regulated
by IL7 (Morrow et al., 1992). To address control of TTP and
Tis11b in this context, primary mouse progenitor B cells grown
in IL7 medium were deprived and then restimulated with ligand.
As expected Myc mRNA levels were dependent upon ligand
(Figure 3A). Notably, control of TTP and to a lesser extent
Tis11b, were the inverse of Myc, where TTP and Tis11b mRNA
levels were high in ligand-deprived cells yet suppressed
following IL7 stimulation. Further, analyses of both B and T
lymphocyte developmental expression (Painter et al., 2011;
Tabrizifard et al., 2004) revealed that TTP and Tis11b levels
were the inverse of those of Myc, where they are induced
when Myc is shut off in more mature, nonproliferating lympho-
cytes (Figure 3B). Thus, TTP and Tis11b expression is regulated
by physiological signals that control Myc.
Myc Suppresses TTP and TIS11B Transcription
P493-6 lymphoblastoid B cells harbor a tetracycline (Tet)-
repressed c-Myc transgene that allows Myc to be turned on
and off (Pajic et al., 2000). To test whether Myc regulates the
expression of AUBPs, these cells were treated with Tet to turn
off Myc. Tet was then removed and cells harvested for expres-
sion analysis. As c-Myc mRNA and protein were induced
(Figure 3C, black line, and data not shown), AUF2 and NCL
mRNA levels also increased, whereas TTP and TIS11B mRNA
levels dropped. In contrast, HUR and AUF1 mRNA levels do
not increase until 24 hr after c-Myc induction, suggesting they
are indirect targets of Myc.
P493-6 cells also harbor an estrogen-regulated ER-EBNA2
fusion transgene that can drive cell proliferation in the presence
of b-estradiol (b-E2) even when c-Myc is repressed by Tet,
allowing one to discriminate direct versus proliferative effects
of Myc. Notably, b-E2 had little effect on TTP and actually
induced TIS11B in the presence of Tet (Figure 3C, red line), sug-566 Cell 150, 563–574, August 3, 2012 ª2012 Elsevier Inc.gesting these are direct targets repressed by Myc. In contrast,
b-E2 induced HUR, AUF1, AUF2, and NCL mRNA levels; thus,
these AUBP genes may be induced via Myc’s proliferative
effects.
Myc:Max complexes can repress transcription by binding to
Inr elements. TTP harbors an Inr downstream of the TATA box
(Lai et al., 1995) and a putative Inr is present in TIS11B near
the TATA box. To test whether Myc bound to these Inr elements,
chromatin immunoprecipitation (ChIP) assays were performed
by using c-Myc antibody in P493-6 cells ± Tet. There was an
inducible enrichment (of 3.5-fold) of Myc binding to the Inr
elements of TTP and TIS11B (Figure 3D and S3A). Further,
genome-wide Myc ChIP analyses of the ENCODE project
(Rosenbloom et al., 2010) showed that Myc binds to the Inr
regions of both TTP and TIS11B in several tumor and normal
cell lines (Figure S3B).
To assess if Myc-mediated repression of TTP and TIS11Bwas
transcriptional, we performed primary transcript (i.e., unspliced)
qRT-PCR analyses and RNA Pol II ChIP analyses in P493-6
cells ± Tet. Myc induction was associated with repression of
nascent TTP transcripts (Figure S3C) and with a marked reduc-
tion in binding of RNA Pol II to the transcription start regions of
both TTP and TIS11B (Figure 3E). Thus, Myc binding to the Inr
elements of TTP and TIS11B is associated with their reduced
transcription.
TTP Impairs Myc-Induced Lymphomagenesis
Given the effects of Myc on TTP and TIS11B expression and
their suppression in Myc-driven lymphoma, we hypothesized
that Myc-directed repression of TTP and/or Tis11b contributes
to lymphomagenesis. To test this, Em-TTP and Em-Tis11b
transgene vectors were generated (Figure 4A) that contained
complete coding regions for mouse TTP or Tis11b (but lacking
their 50 and 30 UTRs) cloned into the pEmSR vector (Bodrug
et al., 1994). These constructs were used to generate Em-TTP
and Em-Tis11b transgenic mice coined Em-TTP-1, Em-TTP-2,
and Em-Tis11b; all expressed elevated levels of TTP or Tis11b
mRNA in B cells (Figure 4B) and the TTP transgenics had high
levels of TTP protein in splenic and BMB220+B cells (Figure 4C).
Em-TTP and Em-Tis11b transgenics mice grow normally and
have no apparent phenotype. Further, analyses of B cell devel-
opment established that overexpression of TTP or Tis11b does
not alter B cell numbers or immunophenotypes (Figure 5C and
data not shown). Indeed, expression analysis showed only 16
genes were significantly altered by elevated TTP expression in
Em-TTP B cells versus wild-type B cells that express endoge-
nous TTP (and only six of these are ARED genes, Figure S4).
Thus, TTP overexpression alone has very minor effects on
B cell gene expression programs.
To test roles of TTP or Tis11b in lymphomagenesis, Em-TTP-1,
Em-TTP-2, or Em-Tis11b transgenics were bred to Em-Myc
mice, and single and double transgenics littermates were
assessed for their premalignant state and tumor-free survival.
As expected, Em-TTP-1, Em-TTP-2, and Em-Tis11b mice never
developed disease and Em-Myc transgenics died at 3–4 months
of age (median survival 103.5 and 121 days; Figure 5A, top and
middle panels). Enforced TTP expression markedly extended
the lifespan of Em-Myc transgenics (median survival, 194 and
Figure 3. Myc Directly Represses TTP and
TIS11B Transcription
(A) qRT-PCR analysis of total RNA isolated from
primary wild-type B220+ B cells grown ex vivo in
the presence of IL7. IL7 was removed at 18 hr
and reintroduced at 0 hr and cells were collected
at the indicated intervals. The relative expression
was determined for c-Myc, TTP, and Tis11b.
Results were normalized to Ubiquitin (Ub)
expression.
(B) Expression of c-Myc, TTP, and Tis11b
throughout mouse B cell (GSE15907) and T cell
(GSE30631) development.
(C) Total RNA was isolated from P493-6 B cells
treated with Tet for 72 hr to repress c-Myc
expression. Cells were either washed to remove
Tet (black lines with circles), allowing Myc activa-
tion, or were treated with b-E2 (red lines with
squares), allowing proliferation via ER-EBNA2
activation. Cells were collected at the indicated
intervals. qRT-PCR analysis was performed to
determine the relative expression of c-Myc, TTP,
TIS11B, HUR, AUF1, AUF2, and NCL, and results
were normalized to Ubiquitin (Ub) expression.
(D and E) ChIP analyses establish that Myc
binds to the initiator element (Inr) found in the
promoters of TTP and TIS11B and that this is
associated with reduced binding of RNA Pol II.
Chromatin was immunoprecipitated with an a-c-
Myc antibody from P493-6 cells with repressed
c-Myc (+Tet) or following 8 hr of c-Myc induction
(-Tet) (D), or with an a-RNA Pol II antibody from
P493-6 cells when c-Myc was repressed by Tet
(0 hr) or following c-Myc induction by removal of
Tet (24 hr) (E). Bound chromatin was evaluated by
qRT-PCR and compared to the total amount of
chromatin. Results show the mean with error bars
indicating ± SEM.
See also Figure S3.277 days for Em-Myc;Em-TTP-1 and Em-Myc;Em-TTP-2; Fig-
ure 5A). In contrast, enforced Tis11b expression did not impair
disease (Figure 5A, bottom panel). Thus, TTP, but not Tis11b,
harnesses Myc-induced lymphomagenesis.
Tumors that ultimately developed in Em-Myc;Em-TTP trans-
genics had phenotypes typical of Em-Myc lymphomas. Silencing
of the Em-TTP or Em-Myc transgenes was not observed, as
tumors expressed high levels of TTP and Myc (Figures 5B and
S5A and S5B). In addition, c-Myc transgene expression is similar
in premalignant bone marrow B cells of Em-Myc;Em-TTP-1 andCell 150, 563–57Em-Myc mice, and there are no differ-
ences in the levels of endogenous c-
Myc transcripts in Em-TTP and wild-type
B cells (Figure S5C). Further, a compar-
ison of the 1697 genes in the Myc target
gene database (http://myc-cancer-gene.
org/) demonstrated that only three
Myc targets differed in Em-Myc versus
Em-Myc;Em-TTP-1 lymphomas (Hlcs,
Ngfrap1 and Asns) and none of these
are ARED genes. Thus, enforced TTPexpression affects neither the expression nor function of the
Myc transgene. Rather, improved survival of Em-Myc;Em-TTP
transgenics was due to a protracted premalignant state where
splenomegaly and increased B cell numbers, hallmarks of
eminent disease in Em-Myc mice, were manifest in 5-week-old
Em-Myc but not Em-Myc;Em-TTP-1 littermates (Figure 5C).
TTP Disables Myc’s Proliferative Response
Premalignant Em-Myc B cells have high rates of proliferation that
are offset by increased apoptosis. TUNEL-FACS analyses4, August 3, 2012 ª2012 Elsevier Inc. 567
Figure 4. Generation of Em-TTP and Em-Tis11b Transgenic Mice
(A) Schematic of Em-TTP and Em-Tis11b transgenes. The complete coding
region for mouse TTP or Tis11b, was cloned into the pEmSR plasmid down-
stream of the SRa promoter. The transgenes also include the mouse Igh 50
enhancer (Em), the rabbit globin poly A and an SV40 tag region.
(B) qRT-PCR analysis of TTP or Tis11b expression in total RNA isolated from
B220+ B cells from wild-type and Em-TTP littermates from two different
founders (Line 1 and Line 2) or from Em-Tis11b littermates. Results were
normalized to Ubiquitin (Ub) expression.
(C) Immunoblots analyses of TTP and Actin levels in bone marrow and splenic
B220+ B cells of wild-type and Em-TTP littermates.
Results show the mean with error bars indicating ± SEM. See also Figure S4.revealed no significant differences in the apoptotic index of
Em-Myc and Em-Myc;Em-TTP-1 B cells (Figure 5D). Myc triggers
apoptosis via induction of Arf and activation of p53; accordingly,
> 70% of Em-Myc lymphomas bear inactivating mutations in
Arf or p53 (Eischen et al., 1999). However, there were no differ-
ences in Arf or p53 expression, or in the frequency of alterations
in Arf or p53, in Em-Myc;Em-TTP-1 versus Em-Myc lymphomas
(Figures S5D and S5E) indicating that TTP does not affect
Myc-induced apoptosis. Surprisingly, Em-TTP-1 BM B cells
had an increased apoptotic index. Only one of the 16 genes in
BM B cells affected by the TTP transgene (Figure S4), Lims1,
has a role in apoptosis. Lims1 encodes Pinch1, which controls
destruction of the proapoptotic BH3-only protein Bim (Chen568 Cell 150, 563–574, August 3, 2012 ª2012 Elsevier Inc.et al., 2008). Indeed, Bim levels were elevated in Em-TTP-1 B
cells (Figure S5F). Regardless, this TTP-directed response is
not manifest in the context of Myc, and it has no obvious effects
on B cell development.
To assess if Myc-induced proliferation was affected by TTP,
wild-type and transgenic littermates were injected with BrdU,
and B220+ cells were collected from BM and spleen and
analyzed by FACS. As expected, Em-Myc B cells had a high
proliferative index, whereas Em-TTP-1 B cells had proliferative
rates similar to wild-type B cells; thus, TTP alone does not affect
B cell growth (Figure 5E). Notably, the proliferative index of Em-
Myc;Em-TTP-1 B cells was significantly reduced compared to
Em-Myc B cells, with the exception of IgM-B220+ BM B cells.
These data indicate that TTP impairs lymphoma development
primarily by disabling Myc’s proliferative response.
TTP Functions as a Tumor Suppressor that Abolishes
the Malignant State
All Em-Myc lymphomas express little if any TTP and Tis11b (Fig-
ure 2). Thus, we hypothesized that TTP and/or Tis11b suppres-
sion was necessary for maintenance of the malignant state. To
test this, an Em-Myc lymphoma was harvested and infected
with MSCV-I-GFP (GFP-only) versus MSCV-TTP-I-GFP (TTP-
GFP) retroviruses, or with GFP-only versus MSCV-Tis11b-I-
GFP (Tis11b-GFP) retroviruses. Transduction efficiencies of
lymphoma cells were similar forGFP-only virus in the two exper-
iments (54% and 61%) and were comparable to those for TTP-
GFP (40%) and Tis11b-GFP (41%) viruses. Unsorted transduced
Em-Myc lymphoma cells were injected intravenously into Nude
mice and followed for tumor development. In both experiments,
recipients developed tumors at a similar rate and frequency,
two to eight tumors per mouse. Tumors and peripheral blood
were collected and GFP expression was assessed. Comparing
the percentage of GFP+ lymphoma cells in the GFP-only versus
TTP-GFP cohort revealed a striking selection against TTP-
expressing tumor cells—a 13-fold drop in lymphoma cells ex-
pressing TTP compared to donor input versus a 1.1-fold drop
in GFP+ lymphoma cells in the GFP-only cohort (Figure 6A). In
contrast, there was less than a 3% change in GFP+ lymphoma
cells in both the GFP-only and Tis11b-GFP cohort versus donor
input (Figure 6A). Thus, there is a strong selection against TTP,
but not Tis11b, expression in Em-Myc lymphoma.
Analysis of peripheral blood B cells from recipients with
lymphomas expressing GFP-only virus showed an average of
47% and 40% GFP+ cells (Figure 6B), whereas those of recipi-
ents with Tis11b-GFP virus averaged 22%. Again, in TTP-GFP-
virus-infected recipients there was a marked selection against
TTP-expressing lymphoma cells, where on average only 8.4%
of B cells were GFP+ (Figure 6B). Further, seven of these nine
recipients had <2% GFP+ B cells; thus, few, if any, lymphoma
cells expressing TTP remained.
To determine if TTP-GFP virus was present in lymphomas
lacking GFP, genomic qPCR copy number and immunoblot
analyses were performed. All tumors from the TTP-GFP cohort
having modest levels of GFP+ cells expressed TTP, whereas
those with no GFP+ cells lacked TTP (Figure S6B). In addition,
genomic qPCR analyses showed that most TTP-GFP tumors
have little to no TTP-GFP virus; thus, TTP-expressing lymphoma
Figure 5. TTP Suppresses Myc-driven Lym-
phomagenesis
(A) Survival curves of Em-Myc;Em-TTP-1 (n = 19),
Em-Myc;Em-TTP-2 (n = 25), and Em-Myc;Em-Tis11b
(n = 23) transgenic mice were compared to Em-
Myc littermates (n = 16, 30 or 22, respectively).
Tick marks above survival curve indicate mice that
were still alive when the analysis was completed.
The p values were determined by using Mantel-
Cox log rank test.
(B) Immunoblots analyses of Myc and Actin levels
in Em-Myc versus Em-Myc;Em-TTP-1 lymphomas.
(C) Splenic mass and numbers of B220+ B cells in
the spleens of 5-week-old wild-type, Em-TTP-1,
Em-Myc, and Em-Myc;Em-TTP-1 littermates.
(D and E) Analysis of TUNEL-positive (D) and
BrdU+ (E) B220+ cells, separated based upon
their IgM expression, from BM and spleen of 5-
week-old wild-type, Em-TTP-1, Em-Myc, and Em-
Myc;Em-TTP-1 mice.
Results show themean with error bars indicating ±
SEM. Student’s t test (*p < 0.05, **p < 0.01, ***p <
0.001). See also Figure S5.cells are out-competed (Figure S6A). There was one exception
where the TTP-GFP virus was present but silenced, indicating
this is another mode of circumventing TTP. In contrast, in the
GFP-only tumors all contain at least some GFP virus. As ex-
pected, Myc expression was sustained in all lymphomas (Fig-
ure S6B). Thus, there is a selection for TTP loss in malignancy.
To assess whether TTP affected lymphoma cell survival or
proliferation, unsorted Em-Myc lymphoma cells infected with
GFP-only, TTP-GFP, or Tis11b-GFP viruses were analyzed
ex vivo. There were no differences in the apoptotic index of
GFP+ versus GFP cells in any of the lymphomas (n = 4, data
not shown). However, there was a rapid reduction in the percent
of GFP+ cells in TTP-GFP-virus-infected, but not in GFP-only or
Tis11b-GFP-virus-infected, lymphomas (n = 4). Indeed, by day 6
there were virtually no GFP+ cells in TTP-GFP virus-infected
lymphoma cultures (Figure 6C). This correlated with striking
reductions in the percent of GFP+ (i.e., TTP-expressing) cells
in S phase and corresponding increases in GFP+ cells in G0/G1
phase (Figure 6D). Thus, TTP abolishes the malignant state by
disabling Myc’s proliferative response.
These data suggested lymphoma cells with low TTP levels
have an advantage in vivo. To test this, we purified GFP+ cells
from GFP-only and TTP-GFP-virus-infected lymphomas and
injected these into Nude mice. Again, TTP-expressing
lymphoma cells took significantly longer to develop into tumorsCell 150, 563–57than GFP-only-expressing lymphoma
(p = 0.005, Figure 6E). Thus, tumorigenic
potential is augmented by suppression
of TTP.
TTP-Dependent Control of its
Targets is Bypassed During
Tumorigenesis
To gain insights into the mechanism of
TTP tumor suppression, expression anal-ysis was performed on premalignant BM B220+ B cells isolated
from wild-type, Em-TTP-1, Em-Myc, and Em-Myc;Em-TTP-1 litter-
mates. This analysis revealed 115 genes significantly differ
between Em-Myc and Em-Myc;Em-TTP-1 B cells (Table S4).
Thirty-six of these are ARED genes, where those repressed
may represent direct TTP targets and those induced may reflect
downstream genes indirectly affected by TTP (Figure 7A). Strik-
ingly, the effects of TTP in premalignant B cells were very selec-
tive because there were no changes on other aspects of mRNA
metabolism or upon other biological processes operational in
cancer (e.g., angiogenesis, metabolism, etc.; Table S5). Notably,
ten of these ARED genes have roles in cancer (Table S6) and
qRT-PCR analyses confirmed six were differentially expressed
in Em-Myc and Em-Myc;Em-TTP-1 B cells. Ccnd1 (Cyclin D1),
which regulates cell cycle and proliferation (Peters, 1994), is
significantly elevated in Em-Myc B cells yet reduced in Em-Myc;
Em-TTP-1 B cells (Figure 7B). Further, Fstl1, a proinflammatory
cytokine (Miyamae et al., 2006), is repressed in Em-Myc;Em-
TTP-1 versus Em-Myc B cells. In contrast, the expression of
ARED genes involved in autophagy (Gabarapl1, Hemelaar
et al., 2003) or apoptosis (Uaca, Sakai et al., 2004), were elevated
in Em-Myc;Em-TTP-1 B cells. Additionally, Tes, a putative tumor
suppressor (Tobias et al., 2001), and Tns3, a metastasis
suppressor (Katz et al., 2007), are reduced in Em-Myc B cells
yet restored to wild-type levels in Em-Myc;Em-TTP-1 B cells.4, August 3, 2012 ª2012 Elsevier Inc. 569
Figure 6. TTP Impairs Maintenance of Em-Myc Lymphoma
(A and B) Nude mice were injected with unsorted Em-Myc lymphoma cells
infected with MSCV-I-GFP versus MSCV-TTP-I-GFP retrovirus (left panel) or
with Em-Myc lymphoma cells infected with MSCV-I-GFP versus MSCV-
Tis11b-I-GFP retrovirus (right panel). Shown is analysis of the change in the
percentage of GFP+ B cells found in tumors compared to the percentage of
GFP+ lymphoma cells that were injected (A) and the percentage of GFP+ B
cells found in peripheral blood (B) at the time of sacrifice. Individual samples
are indicated by circles and the mean for each group is represented by a line.
(C) Percentage of GFP+ unsorted ex vivo Em-Myc lymphoma cells infected
with MSCV-I-GFP versus MSCV-TTP-I-GFP retrovirus (left panel) or with
MSCV-I-GFP versus MSCV-Tis11b-I-GFP retrovirus (right panel) was deter-
mined at the indicated intervals.
(D) Changes in cell cycle distribution of unsorted ex vivo Em-Myc lymphoma
cells infected with MSCV-I-GFP versus MSCV-TTP-I-GFP retrovirus based
upon the presence or absence of GFP within the lymphoma cells (i.e., GFP+
cells minus GFP-negative cells). Cells were labeled with BrdU, harvested and
analyzed by FACS. The graph represents the average of three individually in-
fected plates of Em-Myc lymphoma cells for each retrovirus.
(E) Survival curves of Nude mice injected with Em-Myc lymphoma cells sorted
for GFP+ following infection withMSCV-I-GFP or MSCV-TTP-I-GFP retrovirus.
P values were determined using the Mantel-Cox log rank test.
Results show the mean with error bars indicating ± SEM. Student’s t test (**p <
0.01, ***p < 0.001, *****p < 0.00001). See also Figure S6.Moreover, these ARED genes are induced (Ccnd1 and Fstl1) or
repressed (TES, TNS3, and GABARAPL1) in Em-Myc lymphoma
and BL, and in MYCN-amplified neuroblastoma (Figure 1 and
Figure S1). Finally, these TTP-dependent targets are also regu-
lated by IL7 signaling in primary B cells (Figure S7A), indicating
they are physiological targets of the Myc/TTP circuit.570 Cell 150, 563–574, August 3, 2012 ª2012 Elsevier Inc.A feature of malignant conversion is bypass of regulatory
circuits. Analyses of Em-Myc and Em-Myc;Em-TTP-1 lymphomas
confirmed bypass of five out of six TTP-dependent, cancer-
associated ARED genes (Figure 7C). Specifically, TTP-directed
control of Ccnd1, Gabarapl1, Tes, Tns3, and Uaca were all lost
during the conversion to frank malignancy. Thus, in the presence
of TTP there is a selection for loss of control of its targets during
tumorigenesis.
The most profound effects of TTP were on proliferation and
cyclin D1. Thus, we tested whether, as suggested (Marderosian
et al., 2006), Ccnd1 was a direct target of TTP. Dox-dependent
control of expression of Flag-tagged TTP in HeLa cells led to
marked reductions in endogenous cyclin D1 mRNA and protein
(Figure 7D). Further, ribonucleoprotein immunoprecipitation
(RNP-IP) of HeLa cells transfected with a TTP-Flag vector
established that TTP binding to CCND1 mRNA was enriched
by over 250-fold compared to control transfected cells
(Figure 7D).
To test whether TTP-directed suppression of cyclin D1 is
necessary for the antiproliferative response provoked by TTP
and for the selection against TTP-expression in Em-Myc
lymphoma, we first infected Em-Myc lymphomas with MSCV-
IRES-dsRed2 (RFP-only) or MSCV-D1a-IRES-dsRed2 (D1a-
RFP) retroviruses (this D1a transgene lacks the 30 UTR harboring
TTP recognition elements). dsRed2-expressing cells were puri-
fied and then infected with GFP-only or TTP-GFP virus. Notably,
enforced expression of D1a was not sufficient to override the
selection against TTP-GFP-expressing lymphoma cells or to
overcome effects upon cell proliferation (n = 3, Figures S7B
and S7C). In accord with analyses of Em-Myc;Em-TTP lymphoma
(Figure 7C), TTP did not suppress endogenousCcnd1 in Em-Myc
lymphoma and also did not affect the expression of exogenous
D1a (Figure S7D). Thus, the ability of TTP to target Ccnd1 tran-
script destruction is bypassed in Em-Myc lymphoma and en-
forced D1a expression is not sufficient to override the antiproli-
ferative effects of TTP. These findings are in accord with the
profound and broad effects of TTP on the transcriptome mani-
fest in Em-Myc;Em-TTP versus Em-Myc lymphoma (Figure 7E
and Table S7, 200 genes altered) and following acute TTP
expression in Em-Myc lymphoma cells infected with TTP-GFP
virus (Figure S7E, 1,100 genes altered in GFP+ versus GFP
lymphoma cells).
DISCUSSION
The data presented herein show that Myc indirectly affects the
expression of hundreds of ARED genes, and that this is linked
to transcriptional regulation of AUBPs that control turnover of
their mRNA substrates. The ability of Myc to repress TTP and
TIS11B transcription via binding to Inr elements suggests that
Myc controls some ARE-containing mRNAs via AUBPs. Notably,
the physiological relevance of the Myc-to-AUBP-to-ARED gene
response is clear, where the Myc-to-TTP pathway is operational
during B cell development and is controlled by IL7 signaling, and
where TTP functions as a tumor suppressor that impairs the
development and maintenance of Myc-driven lymphoma (Fig-
ure S7F). Importantly, this pathway is a hallmark of malignancies
with MYC involvement, suggesting that it might be exploited by
Figure 7. TTP-Dependent Myc Targets
Associated with Tumorigenesis
(A and E) Gene expression profiling of arrays
showing ARED genes whose expression is
specifically altered in B220+ BM B cells from
premalignant Em-Myc versus Em-Myc;Em-TTP-1
mice (A) or all genes whose expression is specifi-
cally altered in lymphomas from Em-Myc versus
Em-Myc;Em-TTP-1 mice (E). Genes labeled in (A)
have known roles in cancer. All probe sets shown
have >2.0-fold change and are significantly altered
by unpaired t test analysis (p < 0.05).
(B and C) qRT-PCR analysis of total RNA isolated
from B220+ BM B cells of wild-type and Em-TTP-1
transgenics and from premalignant Em-Myc and
Em-Myc;Em-TTP-1 mice (B) or from wild-type
B220+ splenic B cells and from Em-Myc and Em-
Myc;Em-TTP-1 lymphomas (C). The relative
expression of Ccnd1, Fstl1, Gabarapl1, Tes, Tns3,
and Uaca is shown. Results were normalized to
Ubiquitin (Ub) expression.
(D) qRT-PCR (top left panel) and immunoblot (top
right panel) analyses show the mRNA and protein
levels of TTP-Flag, Cyclin D1 and Actin in HeLa
Tet-Off/TTP-Flag cells that were grown +Dox
(repressed TTP-Flag) or Dox (induced TTP-Flag)
for 48 hr. For RNP-IP analyses (bottom panel),
RNPs were immunoprecipitated with a-Flag anti-
body from control or TTP-Flag-expressing HeLa
cells and used for qPCR detection of cyclin D1
mRNA.
Results show themean with error bars indicating ±
SEM. Student’s t test (*p < 0.05, **p < 0.01, ***p <
0.001). See also Figure S7 and Tables S4–S7.targeted therapies. Given our findings, it is likely that oncogene-
to-AUBP-to-ARED responses are a general feature of cancer
and that they serve as checkpoints or effectors that control
many features of malignancy.
Previous studies suggested that TTPmight play roles in tumor-
igenesis because its substrates include mRNAs encoding the
LATS2 tumor suppressor and the E6-AP ligase that directs p53
destruction (Lee et al., 2010; Sanduja et al., 2009). Further,
TTP can block the tumorigenic potential of immortal v-H-Ras
transformed mast cells (Stoecklin et al., 2003). Finally, low TTP
expression connotes poor outcome in breast cancer (Brennan
et al., 2009).
The most convincing evidence for a role for TTP in cancer
comes from the current studies, where overriding Myc-directedCell 150, 563–57repression of TTP more than doubles the
lifespan of Em-Myc mice, and where TTP
compromises tumor maintenance by
disabling Myc’s proliferative response.
The tumor suppressor roles of TTP are
underscored by the marked selection
against TTP expression in Myc-driven
lymphomas. Although in our studies the
dominant phenotype of TTP is disruption
of Myc’s proliferative response, the ability
of TTP to induce apoptosis might beimportant for its tumor suppressor functions in other contexts
and/or in harnessing transformation by other oncogenes.
A prediction of our findings is that repression of TTP, or one of
its familymembers, is necessary forMyc-induced tumorigenesis.
In accordwith this, TTP suppression is a hallmark ofmany tumors
withMYC involvement, and TIS11D is repressed in others. These
connections do not necessarily connote roles in cancer, where,
for example, both TTP and Tis11b are targets repressed by
Myc, yet only TTP functions as a tumor suppressor. However,
this selectivity in the Em-Myc model does not exclude possible
tumor suppressor roles for TIS11B or TIS11D in other contexts.
TTP knockout mice rapidly develop an autoimmune disease
characterized by cachexia, arthritis, and dermatitis (Taylor
et al., 1996), which are provoked by marked increases in the4, August 3, 2012 ª2012 Elsevier Inc. 571
TTP target TNF-a (Carballo et al., 1998). Thus, crossing TTP
knockout mice to Em-Myc transgenics was not informative.
Loss of Tnfr1 and Tnfr2 abrogates nearly all aspects of the TTP
deficiency (Carballo and Blackshear, 2001); thus, we also gener-
ated Em-Myc;TTP/;Tnfr1/;Tnfr2/ transgenics. Notably,
TTP/;Tnfr1/;Tnfr2/ mice do not develop tumors and the
course of lymphoma onset and survival was similar between
these Em-Myc;TTP+/+ and Em-Myc;TTP/ cohorts (data not
shown). We conclude that TTP loss alone is not sufficient to
provoke tumorigenesis and that Myc-directed suppression of
TTP effectively cancels its tumor suppressor functions.
The Myc/TTP circuit appears operational during lymphopoie-
sis and is controlled by IL7 signaling. However, B cell develop-
ment and proliferation are essentially unaffected by enforced
TTP expression, where phenotypes are not evident even in
aged Em-TTP transgenics. Thus, whereas TTP alone has limited
effects on B cell physiology, it has profound and selective effects
on the development and maintenance of Myc-driven tumors,
supporting the notion that agents targeting TTP may be effective
therapeutics.
Six ARED genes having known roles in cancer were TTP
dependent in precancerous Myc-expressing B cells and TTP-
dependent control of these targets was bypassed in lymphomas,
suggesting important roles for these targets in the conversion to
the malignant state. However, as established by our expression
analyses of Em-Myc;Em-TTP tumors and of Em-Myc lymphoma
transduced with TTP-expressing retrovirus, there are broad
and profound effects of TTP on the cancer transcriptome.
Thus, agents that specifically reactivate TTP expression and/or
augment its activity may be superior to those that affect the
control of any one of its individual targets. Notably, such TTP-
targeting agents would represent attractive therapeutics for the
treatment of malignancies with MYC involvement.
EXPERIMENTAL PROCEDURES
Mice and Tumor Analyses
The coding region for mouse TTP or Tis11b was cloned into the pEmSR
plasmid (Bodrug et al., 1994). The University of Michigan Transgenic Animal
Model Core microinjected the Em-TTP or Em-Tis11b transgenes into fertilized
mouse eggs that were then implanted into pseudopregnant females. Trans-
genic founders were identified by PCR.
Em-Myc transgenic mice were bred to Em-TTP-1, Em-TTP-2, or Em-Tis11b
transgenic mice. Mice were monitored for illness and tumor development. Sick
animals were sacrificed and tumors were collected. Nude mice were used for
Em-Myc lymphoma transplant experiments. All animal studies were approved
by the Scripps Florida institutional animal care and use committee (IACUC).
RNA Preparation and Analyses
RNA from B cells, tumor samples and P493-6 cells was prepared with the
NucleoSpin RNA II kit (Macherey-Nagel). RNA was extracted from 17 BL
tumors by using the RNA/DNA kit (QIAGEN) with institutional review board
approval and after informed consent. RNA was used to prepare cDNA and
qRT-PCR was performed. Data analyses used the DDCt method, where
ubiquitin served as the internal control. Primers are listed in the Extended
Experimental Procedures.
Microarray Expression Profiling Analyses
Biotin-labeled cRNA, prepared from total RNA, was fragmented and hybrid-
ized to Affymetrix GeneChip Mouse Genome 430A microarray (Em-Myc
lymphomas) or Mouse Genome 430 2.0 microarray (precancerous Em-Myc572 Cell 150, 563–574, August 3, 2012 ª2012 Elsevier Inc.and Em-Myc;Em-TTP-1 BM B cells, along with littermate controls, and Em-Myc
and Em-Myc;Em-TTP-1 lymphomas). Microarrays were washed, stained, and
scanned. Microarray data are available from the NCBI GEO database under
Accession GSE32239 and GSE37792. Affymetrix data were normalized based
on GCRMA algorithm and analyzed to generate heatmaps by using Gene-
Spring GX11 (GS GX11, Agilent). Yellow indicates upregulation and blue
denotes downregulation on all heatmaps.
For B cell development expression analysis, data from the Immunological
Genome Project (GSE15907) was imported into GS GX11 and analyzed by
using ExonRMA16 algorithm (Painter et al., 2011). For T cell development anal-
ysis, the GEO database GSE30631 (Tabrizifard et al., 2004) was used and
MAS5 signals were derived using Gene Expression Console software
(Affymetrix).
Western Blot Analyses
B cells or tumor samples were lysed and protein concentration was deter-
mined. Protein was separated on SDS-PAGE, transferred to PVDFmembranes
and blotted for specific antibodies. Antibodies are listed in the Extended
Experimental Procedures.
Cell Culture
Before harvesting, P493-6 cells (Pajic et al., 2000) were cultured in the pres-
ence of Tet (0.1 mg/ml) for 72 hr and replated in media either without Tet or
with b-E2 (1 mM). Em-Myc lymphomas were harvested, homogenized in PBS
with 2% FBS, filtered through a 100 mm strainer and cultured as a single cell
suspension. For IL7 stimulation, BM-derived B cells were washed and replated
in media without IL7 for 18 hr before readdition of IL7. HeLa Tet-OFF/TTP-Flag
cells were maintained in 2 mg/mL doxycycline (Dox) and in the absence of Dox
for 48 hr to induce TTP-Flag expression.
Chromatin Immunoprecipitation
P493-6 B cells were cultured in media with Tet and then without Tet, fixed, and
harvested. Sonicated chromatin was immunoprecipitated with antibodies
specific for Myc (sc-764, Santa Cruz) or RNA Pol II (sc-47701, Santa Cruz)
or isotype matched IgG (GenScript) with magnetic protein G beads (Active
Motif). qRT-PCRwas run on the chromatin and the percent of chromatin bound
by Myc, RNA Pol II, or IgG was determined. Primers are listed in the Extended
Experimental Procedures.
Flow Cytometry
Cell cycle analysis was performed using a BrdU Flow Kit (BD Biosciences).
Mice were injected intraperitoneally with 1 mg of 5-bromo-2-deoxyuridine
(BrdU) and sacrificed after 16 hr. Cells were blocked with FcBlock and stained
with CD45R/B220 and IgM (BD Biosciences). Cultured Em-Myc lymphoma
cells were pulse-labeled in 10 mM BrdU and harvested. Cells were prepared
according to protocol and stained with DAPI and either a-BrdU FITC or
a-BrdU APC.
Apoptotic analysis was performed using an APO-BrdU TUNEL kit (Phoenix
Flow Systems). Cells were blocked with FcBlock and stained with CD45R/
B220 and IgM antibodies. Cells were fixed and BrdU-labeled with terminal de-
oxynucleotidyl transferase (Tdt) and stained with anti-BrdU-FITC mAb.
White blood cells were isolated from spleens and cells were treated with
FcBlock and stained with CD45R/B220 antibody. For cell cycle, apoptotic,
and B cell number analysis, stained cells were analyzed by using a BD LSRII
and BD FACSDiva. Doublets were excluded. Total B cell number was deter-
mined by the number of cells counted multiplied by the percentage of B cells
in each sample.
Peripheral blood and tumors were collected from Nude mice transplanted
with Em-Myc lymphoma cells infected with MSCV-I-GFP, MSCV-TTP-I-GFP,
orMSCV-Tis11b-I-GFP retrovirus. Cells were treatedwith FcBlock and stained
with an Alexa Fluor 647 B220 antibody (BD). Stained cells were analyzed using
aBD FACSCanto II; doublets were excluded and single cells were gated based
on GFP versus Alexa Fluor 647 (B220+).
Lymphoma Cell Infection and Transplantation
293T cells were CaPO4 transfected with MSCV-I-GFP or MSCV-TTP-I-GFP,
pMD1-old-gag pol, and pCAG-Eco added to 23 HEPES Buffered Saline.
Retrovirus was collected and filtered. Em-Myc lymphoma cells were added to
fresh retrovirus with polybrene and centrifuged. Six hours postinfection, media
was replaced with fresh retrovirus with polybrene. Twenty-four hours after
infection Em-Myc lymphoma cells were resuspended in PBS and 3 3 106
unsorted cells or 1 3 106 GFP+ sorted cells were injected via tail vein into
Nude recipients. Peripheral blood and tumors were collected from sick mice.
Ribonucleoprotein Immunoprecipitation (RNP-IP)
HeLa cells were transfected with pcDNA3-Flag-TTP or pcDNA3 vector using
Lipofectamine Plus (Invitrogen). Cells were lysed and cytoplasmic extracts
incubated with a-Flag mAb or mouse IgG precoated to protein A/G PLUS
agarose beads (Santa Cruz) overnight. Total RNA was isolated from beads
using Trizol and used for cDNA synthesis. qPCR reactions were performed
and data normalized to the IgG controls. Primers are listed in the Extended
Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and seven tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2012.06.033.
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